Navigation Links
Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Date:10/21/2010

SAN FRANCISCO, Oct. 21 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer biotherapeutics company, today announced the appointment of Mark P. Backer, Ph.D., to the newly-created position of senior vice president, technical operations. Dr. Backer will be responsible for all aspects of chemistry, manufacturing and controls (CMC) in support of Jennerex's late-stage product, JX-594, as well as pipeline products.

"We are extremely pleased to welcome Mark to our executive management team, as he brings over 30 years of experience leading all aspects of operations in development-stage and commercial biopharmaceutical companies," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "His depth of expertise specifically in viral vaccine manufacturing and process development will be instrumental as we look forward to the initiation of our late stage clinical trials, and the development of our commercial manufacturing strategy for JX-594."

Dr. Backer joins Jennerex after working as principal of Biologics Technical Consulting, where he provided strategic and technical consulting services supporting developers of biological products. Previously, he served as CEO and board member for Vaxart, Inc., a private company focused on developing vector-based oral vaccines. Dr. Backer served as founding chairman and then board member of Molecular Medicine BioServices (now SAFC Biopharma), a viral-based contract manufacturing firm. Dr. Backer also held management positions of increasing responsibility with Protein Design Labs, Aviron (now MedImmune Vaccines), Coulter Pharmaceuticals, Systemix, IDEC, Eli Lilly and Genentech. Dr. Backer holds a BS in chemistry from Stanford University and a Ph.D. in chemical engineering from the University of Washington.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against cancer cells. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jennerex Appoints Lara Longpre to Chief Operating Officer
2. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
3. Jennerex Announces Presentations at Upcoming Conferences
4. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
5. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
6. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
7. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
8. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
9. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
10. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
11. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)...  Lannett Company, Inc. (NYSE: LCI ) today announced ... Prescription for Success Healthcare Conference on December 14, 2016 at 9:20 ... York City . In addition, the company will ... 4 th Annual Boston Healthcare Conference taking place on December ... ...
(Date:12/6/2016)... CONCORD, Mass. , Dec. 6, 2016  Alopexx ... of DI-Leu16-IL2, a recombinant antibody fusion protein (immunocytokine) composed ... antibody recognizes the same target on B cells as ... and cytokine components but is also involved in tumor ... an anti-cancer vaccine effect. The results of the study ...
(Date:12/6/2016)... , Dec. 6, 2016 Diabetes & Obesity ... diabetes and obesity disease cluster is currently dominated by ... type 2 diabetes mellitus (T2DM), and the majority of ... of products, is attributable to these indications. While products ... market presence, there are a large number of these ...
Breaking Medicine Technology:
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... in Dallas, Texas, is condemning "scam operations" carried out by unethical locksmith companies ... these scam operations to a halt. According to Texas Premier Locksmith, these fraudulent ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... The medical ... holidays and winter seasons. One major study analyzing heart attacks among 138,602 people ... August of a given year. We would all agree of course–no time of year ...
(Date:12/7/2016)... Ohio (PRWEB) , ... December 07, 2016 , ... ... in the 2016 BOC Business Brilliance Awards under the Best New Product Launch ... and results achieved through user experience. , BOC Global Events & Training Group ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief ... the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of ... can for this country. , Nancy attributes her patriotic nature to her WWII veteran ...
Breaking Medicine News(10 mins):